Skip to main content

Biomedical research in Urology

In 2023 our group has pushed forward in the laboratory three main areas of research with the corresponding financial support and intellectual protection of the results: (i) use of radiogenomics and artificial intelligence to accurately discriminate between indolent and aggressive prostate cancer (PCa); (ii) study of new strategies to improve PCa diagnosis and management of BRCA-2 carriers (both from a clinical and molecular perspective); (iii) study at the cellular and molecular level the resistance mechanisms to current therapies in order to better understand how it works and try to overcome it finding new possible therapeutic targets. We have generated models of primary cultures ex vivo and studied the mechanisms of progression and resistance to therapy. We have enlarged our collection of PCa liquid biopsies and tissues and provided with some of these samples to Joaquim Mateo´s group at VHIO for a collaborative PDXs collection.

eCORE

  • Cancer

Team

Group Leader
Joan Morote Robles, Anna Santamaria Margalef

Principal Investigator (PI)
Olga Méndez Fernández

Researchers
Senior Researchers: Enric Trilla, Jacques Planas, Mercè Cuadras, Ana Celma, Lucas Regis, Inés de Torres, Maria Eugenia Semidey | Postdoctoral Researcher Marta Barber

PhD Students
Lidia Ramírez

Lab Technicians
David Ruiz

Publications

16
Publications
62.5
%Q1
81.10
Impact Factor
5.07
Average Impact Factor

Campistol M, Triquell M, Regis L, Celma A , de Torres I, Semidey ME, Mast R, Méndez O, Planas P, Trilla T, Morote
Relationship between Proclarix and the Aggressiveness of Prostate Cancer.
J. Mol Diagn Ther. 2023 Jul;27(4):487-498.
DOI: doi: 10.1007/s40291-023-00649-y
IF: 4.476 (Q1)

Morote J, Borque-Fernando A, Triquell M, Campistol M, Servian P, Abascal JM, Planas J, Méndez O, Esteban LM, Trilla E.
Comparison of Rotterdam and Barcelona Magnetic Resonance Imaging Risk Calculators for Predicting Clinically Significant Prostate Cancer.
Eur Urol Open Sci. 2023 May 22:53:46-54.
DOI: doi: 10.1016/j.euros.2023.03.013.
IF: 2.5 (Q2)

Morote J, Borque-Fernando A, Triquell M, Abascal JM, Servian P, Planas J, Méndez O, Esteban LM, Trilla E.
A risk-organised model for clinically significant prostate cancer early detection.
BJUI Compass. 2023 Mar 7;4(4):420-422.
DOI: doi: 10.1002/bco2.230.
IF: 5.969 (Q1)

Paesano N, Catala V, Tcholakian L, Trilla E, Morote J.
A Systematic Review of the Current Status of Magnetic Resonance-Ultrasound Images Fusion Software Platforms for Transperineal Prostate Biopsies.
Cancers (Basel). 2023 Jul 3;15(13):3479.
DOI: doi: 10.3390/cancers15133479.
IF: 5.2 (Q1)

Morote J, Aguilar A, Trilla E.
The Need for Serum Testosterone Measurement with Liquid Chromatography and Tandem Mass Spectrometry in Prostate Cancer Patients Undergoing Castration.
Eur Urol Oncol. 2023 Sep 1:S2588-9311(23)00169-4.
DOI: doi: 10.1016/j.euo.2023.08.008.
IF: 8.2 (Q1)

Projects

Radiogenomics for the prediction of prostate cancer aggressiveness through artificial intelligence (PI20/01666).
Principal Investigator: Juan Morote
Agency: Instituto de Salud Carlos III
Funding: 151.250 €
Period: 2021-2023

Red Federada de Inteligencia Artificial para acelerar la Investigación Sanitaria (MIA.2021.M02.0005).
Principal Investigator: Anna Santamaria Margalef
Agency: Ministerio de Asuntos Económicos y Transformación Digital
Funding: 987.624 €
Period: 2021-2024

Nuevas estrategias para la mejora del diagnóstico y el manejo terapéutico de los portadores de mutaciones en BRCA2 (PI21/00977).
Principal Investigator: Anna Santamaria Margalef
Agency: Instituto de Salud Carlos III
Funding: 159.720 €
Period: 2022-2024

FLUTE: Federated Learning and mUlti-party computation Techniques for prostatE cancer. HORIZON-HLTH-2022-IND-13-02 topic.
Principal Investigator: Olga Méndez/ Juan Morote
Agency: European Union.
Funding: 490.375€
Period: 2023-2025

Incorporación de nuevos métodos de imagen y perfiles moleculares para mejorar el cribado de cáncer de próstata en portadores de mutaciones en genes de las vías de reparación de ADN (PI23/01310).
Principal Investigator: Olga Méndez
Agency: Instituto de Salud Carlos III
Funding: 127.500€
Period: 2024-2026

Patents

INHIBITOR OF MAP KINASE INTERACTING SERINE/THREONINE KINASE 1 (MNK1) AND MAP KINASE INTERACTING SERINE/THREONINE KINASE 2 (MNK2), CANCER THERAPY METHODS AND THERAPEUTIC COMBINATIONS
Priority Number: PCT/EP2020/069459 (WO2021005183)
Priority Date: 09/07/2020
Applicants: Ramon y Cajal, Santiago; Hümmer, Stefan; Castellvi, Josep; Martinez Sáez, Elena; Borrell, José; Teixidó, Jordi; Estrada, Roger; Bou Petit, Elisabeth; Peg, Vicente; Guijarro, Pedro; Santamaria, Anna; Morote, Joan; Suarez, Leticia. 47% VHIR/ 50% IQS /3% CIBERONC

VHIR Annual Report 2023